Medical Tubing and Extrusion

Medical tubing and extrusion technologies

Amplitude Vascular Systems

Stryker enrolls first patient in first-in-human study of AVS IVL in a coronary indication

By

Amplitude Vascular Systems (AVS), now part of Stryker (NYSE:SYK), today announced the first patient enrolled in a new study of its IVL technology. Stryker completed its acquisition of AVS, worth up to $835 million, earlier this month. The company develops intravascular lithotripsy (IVL) technology for treating severely calcified arterial … [Read more...] about Stryker enrolls first patient in first-in-human study of AVS IVL in a coronary indication

Stryker completes acquisition of Amplitude Vascular Systems

By

Stryker (NYSE:SYK) announced today that it completed its acquisition of Amplitude Vascular Systems (AVS) for an undisclosed amount. AVS develops an intravascular lithotripsy (IVL) platform designed to treat calcified peripheral arterial disease (PAD). It uses pulsed CO₂-generated pressure waves delivered uniformly through an IVL balloon … [Read more...] about Stryker completes acquisition of Amplitude Vascular Systems

Stryker makes IVL play with agreement to acquire Amplitude Vascular Systems

By

Stryker (NYSE:SYK) announced today that it entered into a definitive agreement to acquire Amplitude Vascular Systems (AVS) for an undisclosed amount. Portage, Michigan-based Stryker’s latest strategic move marks its planned entry into the intravascular lithotripsy (IVL) space. IVL remains a hot space, with Johnson & Johnson’s Shockwave … [Read more...] about Stryker makes IVL play with agreement to acquire Amplitude Vascular Systems

AVS reports positive results for pulsatile IVL tech

By

Amplitude Vascular Systems (AVS) today announced findings from the first 95 patients treated in its POWER PAD II U.S. pivotal study. POWER PAD II evaluates the company's pulsatile intravascular lithotripsy (PIVL) therapy. It assesses the safety and efficacy of the Pulse IVL system for treating moderate-to-severely calcified peripheral arterial … [Read more...] about AVS reports positive results for pulsatile IVL tech

IVL company AVS opens new HQ ahead of commercial launch

By

Amplitude Vascular Systems (AVS) today announced the opening of its new global headquarters in Waltham, Massachusetts. The new 37,811-square-foot space now serves as the company's hub for innovation, operations and commercialization. It supports the company as it looks to advance its novel Pulse device for pulsatile intravascular lithotripsy … [Read more...] about IVL company AVS opens new HQ ahead of commercial launch

Amplitude Vascular enrolls first patient in IVL study

By

Amplitude Vascular Systems (AVS) announced today that it enrolled the first patient(s) in the U.S. pivotal trial for its intravascular lithotripsy (IVL) technology. Boston-based Amplitude Vascular's POWER PAD II clinical study evaluates the safety of the Pulse IVL system. The company's pulsatile IVL (PIVL) therapy treats patients with moderate … [Read more...] about Amplitude Vascular enrolls first patient in IVL study

AVS is developing a new method of intravascular lithotripsy

By

Amplitude Vascular Systems (AVS) is working on a new way to treat severely calcified arterial disease. The name of the company’s peripheral intravascular lithotripsy (IVL) system is Pulse. The Boston-based startup could start enrolling patients in an investigational device exemption (IDE) study as soon as next year. AVS Chief Operating … [Read more...] about AVS is developing a new method of intravascular lithotripsy